Quanterix to acquire Akoya Biosciences; expands addressable market to $5B

Quanterix Corp

Transaction expected to close in Q2 2025; combined cash at close ~$175M.
Combined installed base of 2,300+ instruments; addressable market grows from $1B to $5B.
Expands Quanterix from neurology into oncology and immunology via Akoya's tissue biomarker platform.
Post-closing, combined company will operate under Quanterix name; integration team being formed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.